Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma

被引：3
|
作者：
Thompson, Ethan G. [1 ]
Jiang, Yue [1 ]
Campbell, Timothy B. [2 ]
Fuller, Jaymes [3 ]
Kaiser, Shari [3 ]
Mashadi-Hossein, Afshin [1 ]
Rytlewski, Julie [1 ]
Martin, Nathan [3 ]
Finney, Olivia [4 ]
Kleinsteuber, Katja [4 ]
Alonzo, Eric [4 ]
Pandya, Chetanya [4 ]
Agarwal, Amit [3 ]
Hege, Kristen [2 ]
Raje, Noopur S. [5 ]
Munshi, Nikhil C. [6 ]
Hause, Ronald J. [1 ]
机构：
[1] Celgene Corp, Seattle, WA USA
[2] Celgene Corp, San Francisco, CA USA
[3] Celgene Corp, Summit, NJ USA
[4] Bluebird Bio Inc, Cambridge, MA USA
[5] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124998
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4328
引用
收藏
页数：4
相关论文
共 50 条
  • [21] EVALUATION OF HEALTH STATUS IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), CAR T CELL THERAPY AGAINST BCMA
    Paula, Rodriguez-Otero
    Michel, Delforge
    Nina, Shah
    Parames-Waran, Hari
    Julia, Braverman
    Andrew, Trigg
    Payal, Patel
    Liping, Huang
    Kristen, Hege
    Sujith, Dhanasiri
    HAEMATOLOGICA, 2021, 106 (10) : 287 - 288
  • [22] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY, IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED KARMMA RESULTS
    Cavo, M.
    Oriol, A.
    San-Miguel, J.
    Kansagra, A.
    Madduri, D.
    Shah, N.
    Moreau, P.
    Yakoub-Agha, I.
    Delforge, M.
    Einsele, H.
    Goldschmidt, H.
    Weisel, K.
    Rambaldi, A.
    Reece, D.
    Rodriguez-Otero, P.
    Petrocca, F.
    Connarn, J.
    Patel, P.
    Huang, L.
    Campbell, T.
    Hege, K.
    Munshi, N.
    HAEMATOLOGICA, 2021, 106 (10) : 5 - 5
  • [23] Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor plus dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma
    Rodriguez-Otero, Paula
    Ayers, Dieter
    Cope, Shannon
    Davies, Faith E.
    Delforge, Michel
    Mojebi, Ali
    Jansen, Jeroen P.
    Weisel, Katja
    Hege, Kristen
    Dhanasiri, Sujith
    LEUKEMIA & LYMPHOMA, 2021, 62 (10) : 2482 - 2491
  • [24] Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results.
    Munshi, Nikhil C.
    Anderson, Larry D., Jr.
    Shah, Nina
    Jagannath, Sundar
    Berdeja, Jesus G.
    Lonial, Sagar
    Raje, Noopur S.
    Siegel, David Samuel DiCapua
    Lin, Yi
    Oriol, Albert
    Moreau, Philippe
    Yakoub-Agha, Ibrahim
    Delforge, Michel
    Petrocca, Fabio
    Connarn, Jamie
    Patel, Payal
    Huang, Liping
    Campbell, Timothy Brandon
    Hege, Kristen
    San Miguel, Jesus
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [25] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-Cell therapy, in patients with relapsed and refractory multiple myeloma: Updated KarMMa results
    Einsele, H.
    Oriol, A.
    San-Miguel, J.
    Kansagra, A.
    Madduri, D.
    Shah, N.
    Moreau, P.
    Yakoub-Agha, I
    Delforge, M.
    Cavo, M.
    Goldschmidt, H.
    Weisel, K.
    Rambaldi, A.
    Reece, D.
    Rodriguez-Otero, P.
    Petrocca, F.
    Connarn, J. N.
    Patel, P.
    Huang, L.
    Campbell, T. B.
    Hege, K.
    Munshi, N. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 120 - 121
  • [26] KARMMA STUDY: CHARACTERIZATION OF CYTOKINE RELEASE SYNDROME (CRS) IN PATIENTS (PTS) WITH MULTIPLE RELAPSE/REFRACTORY MYELOMA (MMRR) TREATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121)
    Albert, Oriol
    Ankit, Kansagra
    Yi, Lin
    Jesus, Berdeja
    Nina, Shah
    Ibrahim, Yakoub-Agha
    Hermann, Einsele
    Alessandro, Rambaldi
    Anna, Truppel-Hartmann
    Everton, Rowe
    Julie, Wang
    Amit, Agarwal
    Timothy, Campbell B.
    Sagar, Lonial
    HAEMATOLOGICA, 2021, 106 (10) : 77 - 78
  • [27] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN MULTIPLE RECALL/REFRACTORY MYELOMA (MMRR): ANALYSIS OF HIGH-RISK PATIENT SUBGROUPS (PTS) FROM THE KARMMA STUDY
    Jesus, San-Miguel
    Noopur, Raje S.
    David, Siegel
    Sundar, Jagannath
    Sagar, Lonial
    Nikhil, Munshi C.
    Philippe, Moreau
    Hartmut, Goldschmidt
    Michele, Cavo
    Anna, Truppel-Hartmann
    Everton, Rowe
    Huang Liping
    Amit, Agarwal
    Julie, Wang
    Timothy, Campbell B.
    Donna, Reece E.
    HAEMATOLOGICA, 2021, 106 (10) : 77 - 77
  • [28] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A CAR T THERAPY TARGETING BCMA, IN PATIENTS WITH MULTIPLE RECLAIMER/REFRACTORY MYELOMA (MMRR): UPDATE FROM THE KarMMa STUDY
    Albert, Oriol
    Jesus, San-Miguel
    Ankit, Kansagra
    Deepu, Madduri
    Nina, Shah
    Philippe, Moreau
    Ibrahim, Yakoub-Agha
    Michel, Delforge
    Michele, Cavo
    Hermann, Einsele
    Hartmut, Goldschmidt
    Katja, Weisel
    Alessandro, Rambaldi
    Donna, Reece
    Paula, Rodriguez-Otero
    Fabio, Petrocca
    Jamie, Connarn N.
    Payal, Patel
    Huang Liping
    Timothy, Campbell B.
    Kristen, Hege
    Nikhil, Munshi C.
    HAEMATOLOGICA, 2021, 106 (10) : 76 - 77
  • [29] ESTIMATION OF POST-INFUSION COSTS OF CARE FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVED IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN THE KARMMA CLINICAL TRIAL
    Hari, P.
    Nguyen, A.
    Pelletier, C.
    Hege, K.
    McGarvey, N.
    Gitlin, M.
    Parikh, K.
    VALUE IN HEALTH, 2021, 24 : S29 - S30
  • [30] Estimation of post-infusion costs of care for patients in the US with relapsed and refractory multiple myeloma (RRMM) who received idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa clinical trial
    McGarvey, November
    Ung, Brian
    Carattini, Thomas
    Campbell, Timothy
    Lee, Abraham
    Patwardhan, Pallavi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S181 - S181
12345